8 November 2023 - Gilead Sciences Korea is seeking insurance coverage of its new drug Trodelvy (sacituzumab govitecan) for the treatment of triple negative breast cancer.

Speaking at a press conference celebrating the launch of the drug at the Plaza Hotel on Tuesday, the company said that it is currently pending presentation before the Cancer Drugs Benefit Appraisal Committee, which is the first gateway to obtaining insurance coverage for cancer treatments.

Read Korea Biomedical Review article